Written By:
Dr. Nathan D Wong
Dr. Nathan D Wong
Published On: 17 Aug, 2022 4:15 PM
ASCVD Risk Reduction in Persons with Hypertriglyceridemia: Role of Icosapent Ethyl
- Substantial ASCVD risk persists despite low levels of LDL-C and elevated TGs, and their remnants account for a portion of this residual risk.
- Combination therapy of statins with fibrates or niacin has not shown effectiveness and is generally not recommended to reduce ASCVD event risk.
- REDUCE-IT was a landmark trial showing that icosapent ethyl 4 g/day in addition to maximally tolerated statin therapy could reduce ASCVD events significantly. However, its impact on TGs appears not to account for all of the substantial benefits of this therapy.
Related FAQs
Familial Hypercholesterolemia
Coronary Calcium Screening and Role in Preventive Cardiology
Non-HDL Cholesterol
Diagnosis of Familial Hypercholesterolemia
Lipid and Lab Reporting
LAI Recommendations for the Use of Bempedoic Acid
Current and Future Treatment of Severe Hypercholesterolemia
Apolipoprotein B
Pillars of Heart Failure Management: Implementation and Outcomes with an Emphasis on SGLT2 Inhibitor and Beta-blockers
Dyslipidemia in Hypertension: Importance of Statins for Primary Prevention
